Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Outcomes in Patients With HER2 Gene-Amplified Metastatic Breast Cancer Treated With First Line Herceptin in Combination With a Taxane: A Phase IV, Prospective, Community Based Study

NCT00097487 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00097487
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00097487 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Outcomes in Patients With HER2 Gene-Amplified Metastatic Breast Cancer Treated With First Line Herceptin in Combination With a Taxane: A Phase IV, Prospective, Community Based Study
Lead sponsor
Genentech, Inc.
Phase
Observational
Overall status
Completed
Start date
November 30, 2000
Completion date
September 30, 2004
Enrollment
1,000
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, metastases